ASHER BIO
Asher Bio is an information technology company that specializes in the fields of CFO Office transformation, profitability, and cost management. It focuses on building and developing better immunotherapy for cancer. The company was founded in 2019 and headquartered in San Francisco, California.
ASHER BIO
Social Links:
Industry:
Biotechnology Therapeutics
Founded:
2019-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.asherbio.com
Total Employee:
11+
Status:
Active
Contact:
650.416.6789
Email Addresses:
[email protected]
Total Funding:
218.15 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Google Font API Google Tag Manager WordPress Google Analytics Google Maps Amazon Global Site Tag Sitelinks Search Box
Similar Organizations
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Cidara Therapeutics
Cidara Therapeutics is a biotechnology company that specializes in the fields of healthcare and therapeutics.
ITeos Therapeutics
ITeos Therapeutics is a biotechnology company that specializes in tumor immunology, cancer immunotherapy, and drug discovery.
Kymera Therapeutics
Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.
Translate Bio
Translate Bio is a biotechnology company that specializes in biotechnology, RNA therapeutics, and rare diseases.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Wellington Management
Wellington Management investment in Series C - Asher Bio
Bristol-Myers Squibb
Bristol-Myers Squibb investment in Series C - Asher Bio
Janus Henderson Investors
Janus Henderson Investors investment in Series C - Asher Bio
Boxer Capital
Boxer Capital investment in Series C - Asher Bio
Third Rock Ventures
Third Rock Ventures investment in Series C - Asher Bio
AstraZeneca
AstraZeneca investment in Series C - Asher Bio
RA Capital Management
RA Capital Management investment in Series C - Asher Bio
Wellington Management
Wellington Management investment in Series B - Asher Bio
Invus
Invus investment in Series B - Asher Bio
Marshall Wace
Marshall Wace investment in Series B - Asher Bio
Key Employee Changes
| Date | New article |
|---|---|
| 2022-06-13 | Asher Bio Appoints Andrea Pirzkall, M.D., as Chief Medical Officer |
Official Site Inspections
http://www.asherbio.com Semrush global rank: 6.77 M Semrush visits lastest month: 1.03 K
- Host name: 151.242.237.35.bc.googleusercontent.com
- IP address: 35.237.242.151
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Asher Bio"
Lighting up only the immune cells that matter | Asher Bio
Jan 8, 2025 At Asher Biotherapeutics, we are pioneering a new approach with our cis‑targeted immunotherapies. Our immunotherapies selectively activate only the immune cell types that …See details»
Asher Bio - Crunchbase Company Profile & Funding
Asher Bio is a biotechnology company that specializes in the fields of therapeutics builds better immunotherapy for cancer.See details»
Careers - Asher Bio
AsherBio, along with other biotech companies, has become aware of a surge in email scams targeting prospective job candidates within our industry. Please be aware that official recruiters …See details»
Asher Biotherapeutics - LinkedIn
Asher Biotherapeutics | 4,021 followers on LinkedIn. Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases. | Asher Bio is a ...See details»
AsherBio 2025 Company Profile: Valuation, Funding
Information on valuation, funding, cap tables, investors, and executives for AsherBio. Use the PitchBook Platform to explore the full profile.See details»
Asher Bio: We build better immunotherapies | Y …
Apr 8, 2022 Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases. Our cis-targeting platform aims to enable selective activation of specific immune cell types, …See details»
Asher Bio - Craft
Asher Bio (also known as Asher Biotherapeutics) is a biotechnology company developing cis-targeted immunotherapies for cancer and other diseases. It offers beneficial immunotherapies …See details»
Asher Biotherapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Asher Bio was founded by Ivana Djuretic and Andy Yeung with support from Third Rock Ventures and is located in South San Francisco. For more information, please visit and follow us on X …See details»
Asher Bio - zoonop.com
April 2022: Asher Bio entered into a manufacturing agreement with ProBioGen, a contract development and manufacturing organization (CDMO), to scale up the production of its lead …See details»
Asher Bio | VentureRadar
Asher Biotherapeutics is pioneering a new immunotherapy approach with our cis-targeted immunotherapies. Our immunotherapies selectively activate only the immune cell types that …See details»
Asher Bio Appoints Leading Experts in Immunology, Oncology and …
Jun 14, 2021 Asher Bio is backed by Third Rock Ventures and is located in South San Francisco. For more information, please visit www.asherbio.com and follow us on Twitter …See details»
Our Platform - Asher Bio
Our proprietary cis-targeting platform is designed to overcome the clinical limitations of immune-based therapies. Along with delivering the desired therapeutic effects through interaction with …See details»
Ivana Djuretic - Co-Founder, Chief Scientific Officer - Crunchbase
Primary Job Title Co-Founder, Chief Scientific Officer Primary OrganizationSee details»
Asher drops 60% of staff to zero in on lead immunotherapy
Dec 19, 2023 Small immunotherapy biotech Asher Bio has reduced its workforce by 60%, sending 34 employees on their way and pivoting to a single immunotherapy.See details»
Asher Bio Closes $55 Million Series C Financing to Advance Lead …
Apr 16, 2024 Asher Bio plans to use the proceeds from this financing to advance the clinical development of its lead program, AB248, a novel CD8+ T cell selective IL-2, generated by …See details»
Asher Bio Closes $108 Million Series B Financing - Asher Bio
Sep 1, 2021 Asher Bio was founded by Ivana Djuretic and Andy Yeung with support from Third Rock Ventures and is located in South San Francisco. For more information, please visit …See details»
Asher Bio Announces Clinical Trial Collaboration and Supply …
Jan 8, 2025 "This clinical trial collaboration and supply agreement with Amgen allows us to further expand on the Phase 1 results for etakafusp alfa in a new combination with …See details»
Establishing Canada’s first large-scale bioinnovation centre
2 days ago The Neptune BioInnovation Centre (NBC), a 51,000 sq ft facility on a 12.3 acre lot in Dartmouth, will offer leasable wet and dry lab space, warehouse and office spaces, and …See details»
NEWS - asherbio.com
Jan 8, 2025 South San Francisco, Calif., January 8, 2025 – Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer and …See details»
Pipeline - Asher Bio
We are advancing a pipeline of highly differentiated, precisely targeted immunotherapies in cancer and infectious diseases.See details»